Member Directory

BioIVT is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. And as the premier supplier of hepatic products, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science.

The Greater Munich Area is the location of a longstanding, unique network of a strong Life Science industry, scientific institutions and clinics – a network coordinated by BioM Biotech Cluster Development GmbH (BioM). BioM also manages the Bavarian Biotech Cluster of all life science regions in Bavaria. Altogether, 320 life science companies are located in the Greater Munich Area, in Regensburg and Würzburg.. . BioM is a publicly funded service and consulting company with the aim to promote the development of the Munich Biotech Cluster as an internationally renowned centre of excellence in the field of innovative biotechnology and to link its work closely with the other Bavarian biotech regions. BioM supports local biotech start-up companies with a wide variety of services and training tools. Through the network of all important stakeholders in the region, BioM assists Bavarian-based companies in finding the right contacts and partners, also with regards to international markets.

Founded in 2004, BioMed Realty Trust, Inc. (NYSE: BMR; www.biomedrealty.com) delivers optimal real estate solutions for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities in the life science industry. Currently, the company has over $5 billion invested in the state-of-the-art research facilities representing more than 13 million square feet across the United States and the United Kingdom.

BioMedica is your CDMO partner for in-vitro diagnostic and biopharmaceutical product development. Expanding on our core competencies in thrombosis and haemostasis, we combine our operational expertise in formulation, blending, dispensing, lyophilization with over twenty years of experience in submitting for and obtaining regulatory approvals to collaborate internationally with technology development companies and healthcare stakeholders to develop and manufacture customized reagents and diagnostic solutions. Our focus is on providing custom, affordable diagnostic solutions in the global, human and animal health arenas. Working hard to lower costs and reduce and mitigate risks to all stakeholders, BioMedica develops the tools needed for research, education and In-Vitro Diagnostics. With products and technologies in over 70 countries, BioMedica brings innovation, quality, and affordable diagnostic solutions to an ever-growing group of international partners focused on helping to improve patient outcomes.
Helping people live better lives – it’s not only our vision, it’s what we do.

BioMedica Diagnostics has a very competent team to assist with Development, Quality Systems, as well as Manufacturing requirements of your projects within the Life Science sector within our ISO 13485:2016 - MDSAP accredited facility.

BioNJ, The Gateway to Health, is a powerful network of 400 Member Investors representing research-based life sciences companies and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount. Because Patients Can’t Wait, BioNJ is committed to the growth and prosperity of New Jersey’s life sciences ecosystem to help accelerate the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society. As the industry’s voice in New Jersey, we fulfill our Mission to help our Members help Patients by driving capital formation and fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources. For more information about BioNJ, please visit www.BioNJ.org.

Bionow is a specialist business development and services company focused on the biomedical industry in the North of England. We provide innovative products and services that deliver tangible value, enabling our members to be the most productive and competitive in the world. Our offering spans procurement, insurance, recruitment training and consultancy plus specialist events (both local and national) and access into a large, vibrant network of businesses, universities and NHS organisations. Commenced in July 2011 and already bringing benefit to over 160 subscribing members the Bionow membership scheme offers significant bottom line savings.

BioPartner UK is the independent, accredited trade organisation that promotes international partnering for trade, investment and collaborations with UK life science enterprises. BioPartner’s UK Delegations promote the UK presence at international conferences. We work with conference organisers, in-country agencies and overseas networks to provide the best business opportunities for our members and UK companies travelling with outward delegations. BioPartner also provides access to government grants and entry fee discounts for all UK-based organisations.

BioPharmaLogic Ltd expedits all aspects of nonclinical drug development from pharmacology to post-licensing regulatory activity and life cycle management.

Contract manufacturer of biologics for immunodiagnostic, bio-pharmaceutical and environmental biotechnology applications. Contract RD; creation, development and optimisation of cell lines; process development and validation; production and purification of proteins (milligram to multi-gram quantities)to enable characterisation, pre-clinical testing, and scale-up for clinical trials.. Specialist in hybridoma technology and production/purification of monoclonal antibodies and recombinant proteins from mammalian cell lines. . . Development of bioassays for environmental monitoring. Microbial and monoclonal antibody-based bioassays for identifying pathogens and determining toxicity of wastewater and groundwater.. . Technologies: Hollowfibre bioreactors; spinner/roller culture; stirred vessel bioreactors; Affinity, ion-exchange and size exclusion chromatography.

BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. We also represent state and regional biotech associations, service providers to the industry and academic centers. Visit the BIO Member Directory to browse BIO members and Web site links as well as BIO state and international affiliates.. . Member services include: . * Federal and state advocacy on issues affecting the industry . * A dozen or more investor and partnering meetings throughout the year, with discounts for members . * Communications services that disseminate information about the benefits of biotechnology . * BIO Business Solutions discounts for a variety of goods and services . . Specific issues may have changed over the years, but our core mission of fostering biotechnology innovation through advocacy, business development and communications remains the same. . . BIO produces the annual BIO International Convention, the world's largest gathering of the biotechnology industry. The BIO International Convention attracts more than 20,000 attendees from around the world including more than 500 members of the international press. Convention attendees hear from global biotechnology leaders, learn about the latest biotech innovations and network with their peers from established and emerging biotech companies, research institutions, service providers and biotech hubs.. . BIO also produces a series of industry-leading investor and partnering meetings held around the world.

Pages